NASDAQ:GMTX

Gemini Therapeutics Stock Forecast, Price & News

$10.84
-0.38 (-3.39 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.68
Now: $10.84▼
$11.22
50-Day Range
$11.01
MA: $14.54▼
$18.00
52-Week Range
$10.57
Now: $10.84▼
$19.08
Volume116,750 shs
Average Volume282,030 shs
Market Capitalization$466.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Gemini Therapeutics logo

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMTX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.geminitherapeutics.com
Phone617 678 3113
Employees29
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares42,999,000
Market Cap$466.11 million
Next Earnings DateN/A
OptionableOptionable

Headlines

-$0.32 Earnings Per Share Expected for Gemini Therapeutics, Inc. (NASDAQ:GMTX) This Quarter
April 17, 2021 |  americanbankingnews.com
Gemini Therapeutics (NASDAQ:GMTX) Shares Gap Down to $11.77
April 14, 2021 |  americanbankingnews.com
Gemini Therapeutics (NASDAQ:GMTX) Now Covered by Analysts at SVB Leerink
April 14, 2021 |  americanbankingnews.com
Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 13, 2021 |  finance.yahoo.com
Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
April 12, 2021 |  finance.yahoo.com
Brokers Set Expectations for Gemini Therapeutics, Inc.'s Q1 2021 Earnings (NASDAQ:GMTX)
April 12, 2021 |  americanbankingnews.com
Gemini Therapeutics (NASDAQ:GMTX) Trading Down 5.9%
April 9, 2021 |  americanbankingnews.com
Gemini Therapeutics (NASDAQ:GMTX) Shares Gap Up to $13.52
April 8, 2021 |  americanbankingnews.com
Gemini Therapeutics (NASDAQ:GMTX) Earns Outperform Rating from Analysts at SVB Leerink
April 8, 2021 |  americanbankingnews.com
Gemini Therapeutics (NASDAQ:GMTX) Trading 4.4% Higher
April 7, 2021 |  americanbankingnews.com
FS Development Corp. (NASDAQ:GMTX) Expected to Post Q1 2021 Earnings of ($0.32) Per Share
April 1, 2021 |  americanbankingnews.com
Why does Australia need a Women’s Economic Security Minister?
March 31, 2021 |  au.finance.yahoo.com
AIAG Announces 4,000th Member Company
March 31, 2021 |  sg.finance.yahoo.com
FS Development (NASDAQ:GMTX) Stock Price Down 1.9%
March 31, 2021 |  americanbankingnews.com
Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
March 29, 2021 |  finance.yahoo.com
GMTX.OQ - Gemini Therapeutics Inc Profile | Reuters
March 4, 2021 |  reuters.com
Gemini Therapeutics Inc
March 2, 2021 |  reuters.com
Forsite Capital's third SPAC Foresite Life Sciences files for a $250 million IPO
February 26, 2021 |  nasdaq.com
Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021 |  finance.yahoo.com
Foresite Capital's SPAC FS Development II prices further upsized $175 million IPO
February 17, 2021 |  nasdaq.com
See More Headlines

MarketRank™

Overall MarketRank™

1.70 out of 5 stars

Medical Sector

259th out of 2,018 stocks

Biotechnology Industry

21st out of 147 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$10.84
-0.38 (-3.39 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gemini Therapeutics (NASDAQ:GMTX) Frequently Asked Questions

Is Gemini Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemini Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Gemini Therapeutics stock.
View analyst ratings for Gemini Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Gemini Therapeutics?

Wall Street analysts have given Gemini Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gemini Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for GMTX?

4 brokerages have issued 12 month price targets for Gemini Therapeutics' shares. Their forecasts range from $20.00 to $25.00. On average, they anticipate Gemini Therapeutics' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.
View analysts' price targets for Gemini Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Gemini Therapeutics' key executives?

Gemini Therapeutics' management team includes the following people:
  • Mr. Jason Patrick Meyenburg M.B.A., M.D., CEO, Pres & Director (Age 44, Pay $530.29k)
  • Dr. Scott Lauder Ph.D., Chief Technology Officer (Age 57, Pay $480.3k)
  • Dr. Marc E. Uknis F.A.C.S., M.D., Chief Medical Officer (Age 56, Pay $397.39k)
  • Mr. Brian Piekos, CFO & Principal Accounting and Financial Officer (Age 46)
  • Dr. Walter Strapps, Chief Scientific Officer
  • Ms. Precillia Redmond, Chief People Officer

Who are some of Gemini Therapeutics' key competitors?

Some companies that are related to Gemini Therapeutics include ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), Cullinan Oncology (CGEM), Nurix Therapeutics (NRIX), Silverback Therapeutics (SBTX), Cricut (EWTX), Concordia International (CXR), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Kinnate Biopharma (KNTE), Vor Biopharma (VOR), Connect Biopharma Holdings Limited American Depositary Shares (CNTB), Bolt Biotherapeutics (BOLT) and Oxford Biomedica (OXB).
View all of GMTX's competitors.

What is Gemini Therapeutics' stock symbol?

Gemini Therapeutics trades on the NASDAQ under the ticker symbol "GMTX."

How do I buy shares of Gemini Therapeutics?

Shares of GMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gemini Therapeutics' stock price today?

One share of GMTX stock can currently be purchased for approximately $10.84.

How much money does Gemini Therapeutics make?

Gemini Therapeutics has a market capitalization of $466.11 million.

How many employees does Gemini Therapeutics have?

Gemini Therapeutics employs 29 workers across the globe.

What is Gemini Therapeutics' official website?

The official website for Gemini Therapeutics is www.geminitherapeutics.com.

How can I contact Gemini Therapeutics?

The company can be reached via phone at 617 678 3113.


This page was last updated on 4/21/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.